XML 49 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated balance sheets - EUR (€)
€ in Millions
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Assets      
Property, plant and equipment € 10,160 € 9,869 € 10,028
Right-of-use assets 1,654 1,815 1,948
Goodwill 49,404 49,892 48,056
Other intangible assets 24,319 21,640 21,407
Investments accounted for using the equity method 424 677 250
Other non-current assets 3,218 3,095 3,127
Non-current income tax assets 188 242 175
Deferred tax assets 6,427 5,381 4,598
Non-current assets 95,794 92,611 89,589
Inventories 9,666 8,960 8,715
Accounts receivable 8,433 8,424 7,568
Other current assets 3,455 3,532 3,571
Current income tax assets 391 374 612
Cash and cash equivalents 8,710 12,736 10,098
Current assets 30,655 34,026 30,564
Assets held for sale or exchange 15 85 89
Total assets 126,464 126,722 120,242
Equity and liabilities      
Equity attributable to equity holders of Sanofi 74,040 74,784 68,681
Equity attributable to non-controlling interests 313 368 350
Total equity 74,353 75,152 69,031 [1]
Long-term debt 14,347 14,857 17,123
Non-current lease liabilities 1,755 1,904 1,839
Non-current liabilities related to business combinations and to non-controlling interests 501 674 577
Non-current provisions and other non-current liabilities 7,602 6,341 6,721
Non-current income tax liabilities 1,842 1,979 2,039
Deferred tax liabilities 1,857 1,841 1,617
Non-current liabilities 27,904 27,596 29,916
Accounts payable 7,328 6,813 6,180
Current liabilities related to business combinations and to non-controlling interests 208 105 137
Current provisions and other current liabilities 13,741 12,021 11,217
Current income tax liabilities 597 574 309
Current lease liabilities 275 277 269
Short-term debt and current portion of long-term debt 2,045 4,174 3,183
Current liabilities 24,194 23,964 21,295
Liabilities related to assets held for sale or exchange 13 10 0
Total equity and liabilities € 126,464 € 126,722 € 120,242
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.